The convergence of ubiquitous smartphones, wireless Internet, and low-cost monitoring devices, is driving the emergence of a new world of digital health. At the same time, cost pressures on healthcare are creating demand for new ways to not just improve the way patients receive information and care and the way doctors provide it, but fundamentally change the way they interact with each other. The article discusses a venture capitalist's approach to investing in the sector.
Full details at the Journal of Commercial Biotechnology
In keeping with an emerging literature on the role of business education in the development of entrepreneurially-intentioned biotechnologists, this paper describes the actions and experiences of an entrepreneurship program that began in the late 1990’s. Along the way it illustrates how a business-centric approach can shift the budding entrepreneur’s perspective from a product to a market orientation when considering an innovation’s commercialization. While the developmental timeline and specific stages of the adoption process for biotechnology-based products vary from traditional consumer or industrial products, there many similarities, foremost is the notion that to be successful the market must perceive significant advantage to the new offering. Lastly, this paper provides thoughts on potentially profitable areas for program expansion and new foci, especially regarding the globalization of biotechnology innovation and international opportunities.Full details at the Journal of Commercial Biotechnology
There is a wide body of literature on biotechnology clusters. However, most of the works has been focused on the description of the clusters as well as the development of biotechnology clusters in USA, Europe and other developed countries. Much less attention has been paid to the development of biotechnology clusters in developing countries. The aim of this paper is to gain a better understanding of the emergence of biotechnology clusters in Egypt and South Africa.Full details at the Journal of Commercial Biotechnology
The debates over the Obama Administration’s health care reform law, and, more recently, the federal budget deficit and national debt have focused attention on the growth in costs of the Medicare program. Three approaches to reducing Medicare expenditures command the most attention. Under the first, changes to the Medicare delivery system – such as accountable care organizations (ACOs) and medical homes – are believed to have the potential to reduce the growth in costs in the program over time. Under the second, tinkering with the reimbursement formulae in the Medicare program – pejoratively, government “price fixing” – will reduce the price that Medicare pays for an item or service, thereby reducing the growth in costs. A third approach – converting Medicare to a premium support or defined contribution model – has been passed by the House of Representatives, but has failed in the United States Senate.
This article addresses the effect of these various approaches on Medicare payment for outpatient prescription drugs and biotechnology products. It begins by analyzing the Administration’s ACO regulation and the effect that this regulation may have on reimbursement for outpatient prescription drugs and biotechnology products. It then addresses legislative proposals to alter the Medicare reimbursement formulae for these products. It concludes by speculating on how the Medicare reform legislation passed by the House of Representatives might affect reimbursement for outpatient prescription drugs and biotechnology products.Full details at the Journal of Commercial Biotechnology